Exviera

Nchi: Umoja wa Ulaya

Lugha: Kiingereza

Chanzo: EMA (European Medicines Agency)

Nunua Sasa

Taarifa za kipeperushi Taarifa za kipeperushi (PIL)
16-05-2018
Tabia za bidhaa Tabia za bidhaa (SPC)
16-05-2018

Viambatanisho vya kazi:

dasabuvir sodium

Inapatikana kutoka:

AbbVie Ltd

ATC kanuni:

J05AP09

INN (Jina la Kimataifa):

dasabuvir

Kundi la matibabu:

Antivirals for systemic use,

Eneo la matibabu:

Hepatitis C, Chronic

Matibabu dalili:

Exviera is indicated in combination with other medicinal products for the treatment of chronic hepatitis C (CHC) in adults. For hepatitis C virus (HCV) genotype specific activity.,

Bidhaa muhtasari:

Revision: 14

Idhini hali ya:

Authorised

Idhini ya tarehe:

2015-01-14

Taarifa za kipeperushi

                                57
B. PACKAGE LEAFLET
58
PACKAGE LEAFLET: INFORMATION FOR THE PATIENT
EXVIERA 250 MG FILM-COATED TABLETS
dasabuvir
This medicine is subject to additional monitoring. This will allow
quick identification of new
safety information. You can help by reporting any side effects you may
get. See the end of section 4
for how to report side effects.
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side effects
not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1. What Exviera is and what it is used for
2. What you need to know before you take Exviera
3. How to take Exviera
4. Possible side effects
5. How to store Exviera
6. Contents of the pack and other information
1.
WHAT EXVIERA IS AND WHAT IT IS USED FOR
Exviera is an antiviral medicine used to treat adults with chronic
(long-term) hepatitis C (an infectious
disease that affects the liver, caused by the hepatitis C virus). It
contains the active substance
dasabuvir.
Exviera works by stopping the hepatitis C virus from multiplying and
infecting new cells, thus
clearing the virus from your blood over a period of time.
Exviera tablets do not work on their own. They are always taken with
another antiviral medicine
containing ombitasvir/paritaprevir/ritonavir. Some patients may also
take an antiviral medicine called
ribavirin. Your doctor will talk with you about which of these
medicines to take with Exviera.
It is very important that you also read the package leaflets for the
other antiviral medicines that you
take with Exviera. If you have any questions about your medicines,
please ask your doctor or
pharmacist.
2.
W
                                
                                Soma hati kamili
                                
                            

Tabia za bidhaa

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
This medicinal product is subject to additional monitoring. This will
allow quick identification of
new safety information. Healthcare professionals are asked to report
any suspected adverse reactions.
See section 4.8 for how to report adverse reactions
.
1.
NAME OF THE MEDICINAL PRODUCT
Exviera 250 mg film-coated tablets
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Each film-coated tablet contains 250 mg of dasabuvir (as sodium
monohydrate).
Excipient with known effect: each film-coated tablet contains 44.94 mg
lactose (as monohydrate).
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Film-coated tablet (tablet).
Beige, ovaloid, film-coated tablets with dimensions of 14.0 mm x 8.0
mm and debossed on one side
with ‘AV2’.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Exviera is indicated in combination with other medicinal products for
the treatment of chronic
hepatitis C (CHC) in adults (see sections 4.2, 4.4 and 5.1).
For hepatitis C virus (HCV) genotype specific activity, see sections
4.4 and 5.1.
4.2
POSOLOGY AND METHOD OF ADMINISTRATION
Treatment with Exviera should be initiated and monitored by a
physician experienced in the
management of chronic hepatitis C.
Posology
The recommended dose of dasabuvir is 250 mg (one tablet) twice daily
(morning and evening).
Exviera must not be administered as monotherapy. Exviera should be
used in combination with other
medicinal products for the treatment of HCV (see section 5.1). Refer
to the Summary of Product
Characteristics of the medicinal products that are used in combination
with Exviera.
The recommended co-administered medicinal product(s) and treatment
duration for Exviera
combination therapy are provided in table 1.
3
TABLE 1. RECOMMENDED CO-ADMINISTERED MEDICINAL PRODUCT(S) AND
TREATMENT DURATION FOR
EXVIERA BY PATIENT POPULATION
PATIENT POPULATION
TREATMENT*
DURATION
GENOTYPE 1B, WITHOUT CIRRHOSIS OR
WITH COMPENSATED CIRRHOSIS
Exviera +
ombitasvir/paritaprevir/ritonavir
12 weeks
8 w
                                
                                Soma hati kamili
                                
                            

Nyaraka katika lugha zingine

Taarifa za kipeperushi Taarifa za kipeperushi Kibulgaria 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kibulgaria 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kibulgaria 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihispania 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kihispania 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihispania 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kicheki 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kicheki 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kicheki 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kidenmaki 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kidenmaki 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kidenmaki 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kijerumani 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kijerumani 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kijerumani 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiestonia 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiestonia 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiestonia 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kigiriki 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kigiriki 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kigiriki 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifaransa 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kifaransa 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifaransa 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiitaliano 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiitaliano 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiitaliano 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilatvia 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kilatvia 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilatvia 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kilithuania 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kilithuania 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kilithuania 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kihungari 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kihungari 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kihungari 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kimalta 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kimalta 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kimalta 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiholanzi 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiholanzi 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiholanzi 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kipolandi 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kipolandi 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kipolandi 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kireno 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kireno 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kireno 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiromania 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiromania 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiromania 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovakia 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kislovakia 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovakia 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kislovenia 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kislovenia 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kislovenia 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kifinlandi 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kifinlandi 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kifinlandi 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kiswidi 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiswidi 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kiswidi 08-02-2018
Taarifa za kipeperushi Taarifa za kipeperushi Kinorwe 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kinorwe 12-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kiaisilandi 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kiaisilandi 12-08-2022
Taarifa za kipeperushi Taarifa za kipeperushi Kroeshia 12-08-2022
Tabia za bidhaa Tabia za bidhaa Kroeshia 12-08-2022
Ripoti ya Tathmini ya umma Ripoti ya Tathmini ya umma Kroeshia 08-02-2018

Tafuta arifu zinazohusiana na bidhaa hii

Tazama historia ya hati